Literature DB >> 14567106

[Adverse effects of antiretroviral therapy. Aspects of pathogenesis].

U Seybold1, R Draenert, F D Goebel.   

Abstract

Highly active antiretroviral therapy has resulted in remarkable reduction of morbidity and mortality of HIV infection. With increasing duration of therapy metabolic alterations such as hyperlipidemia, diabetes mellitus type 2 and lipodystrophy are encountered which considerably reduced quality of life for the patients. These adverse events are most likely due to protease inhibitors and nucleoside analogues with synergistic effects. The pathogenesis is related to metabolic alterations of the adipocytes with cellular insulin resistance and enhanced apoptosis of these cells caused by adipocytic cytokines such as adiponectin, leptin, TNF-alpha and interleukin 2. Switch of therapy regimens with elimination of the most suspicious substances and certain protease inhibitors can lead to improvement of deranged metabolism. Also symptomatic therapy is possible to cope with hyperlipidemia and diabetes, although no effective treatment is available to reverse already existing lipodystrophy. Our knowledge about the pathogenesis of these alterations might lead to new concepts and causal therapy in the future.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14567106     DOI: 10.1007/s00108-003-0927-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  45 in total

1.  Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir.

Authors:  R K Walli; G M Michl; J R Bogner; F D Goebel
Journal:  Eur J Med Res       Date:  2001-10-29       Impact factor: 2.175

2.  FDA warns of potential protease-inhibitor link to hyperglycaemia.

Authors:  A Ault
Journal:  Lancet       Date:  1997-06-21       Impact factor: 79.321

3.  Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy.

Authors:  Georg M N Behrens; Anne-Rose Boerner; Klaus Weber; Joerg van den Hoff; Johann Ockenga; Georg Brabant; Reinhold E Schmidt
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

4.  Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy.

Authors:  M Schmitz; G M Michl; R Walli; J Bogner; A Bedynek; D Seidel; F D Goebel; T Demant
Journal:  J Acquir Immune Defic Syndr       Date:  2001-03-01       Impact factor: 3.731

5.  Human obesity and type 2 diabetes are associated with alterations in SREBP1 isoform expression that are reproduced ex vivo by tumor necrosis factor-alpha.

Authors:  Ciaran Sewter; Dirk Berger; Robert V Considine; Gema Medina; Justin Rochford; Theodore Ciaraldi; Robert Henry; Lynis Dohm; Jeffrey S Flier; Stephen O'Rahilly; Antonio J Vidal-Puig
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

6.  Indinavir induces acute and reversible peripheral insulin resistance in rats.

Authors:  Paul W Hruz; Haruhiko Murata; Haijun Qiu; Mike Mueckler
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

7.  Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database.

Authors:  K V Heath; R S Hogg; K J Chan; M Harris; V Montessori; M V O'Shaughnessy; J S Montanera
Journal:  AIDS       Date:  2001-01-26       Impact factor: 4.177

8.  Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.

Authors:  Samuel A Bozzette; Christopher F Ake; Henry K Tam; Sophia W Chang; Thomas A Louis
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

9.  Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection.

Authors:  Ellen S Engelson; Marshall J Glesby; Douglas Mendez; Jeanine B Albu; Jack Wang; Steven B Heymsfield; Donald P Kotler
Journal:  J Acquir Immune Defic Syndr       Date:  2002-08-01       Impact factor: 3.731

10.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.

Authors:  A Carr; K Samaras; S Burton; M Law; J Freund; D J Chisholm; D A Cooper
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.